Loading organizations...
§ Private Profile · 80 M St SE Ste 100, Washington, District of Columbia 20005, US
Precision neurology technology company with FDA Breakthrough Device Designation. Digital NeuroMarker Platform detects early Alzheimer's & MCI.
Founded in 2016 by Ioannis Tarnanas and Richard Fischer, Washington DC based Altoida is a precision neurology technology company that develops an artificial intelligence and augmented reality based digital biomarker platform to assess cognitive function and detect early signs of Alzheimer's disease. The business generates revenue by licensing its proprietary ten minute smartphone and tablet assessments to pharmaceutical companies, healthcare providers, and clinical researchers. Backed by over twenty years of research, the breakthrough diagnostic platform has been utilized in tens of thousands of assessments involving nearly twenty thousand participants. Altoida currently operates with an estimated eleven to fifty employees and has raised over twenty million dollars in total venture funding, including a fourteen million dollar Series A round. The enterprise is backed by notable corporate investors such as M Ventures, Eisai Innovation, Hikma Ventures, and Swisscom Ventures.
Altoida has raised $21.0M across 3 funding rounds.
Altoida has raised $21.0M in total across 3 funding rounds.
Altoida has raised $21.0M in total across 3 funding rounds.
Altoida's investors include M Ventures (Merck), Fyrefly VC, Taiho Ventures, Tomahawk.VC, Alpana Ventures, btov Partners, Hikma Ventures, HonorHealth, VI Partners, Alexander Hoffmann, ALPANA Ventures, Maximon.
Altoida has raised $21.0M across 3 funding rounds. Most recently, it raised $14.0M Series A in March 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2022 | $14M Series A | M Ventures | Fyrefly VC, Taiho Ventures, Tomahawk.vc, Alpana Ventures, Btov Partners, Hikma Ventures, Honorhealth, VI Partners | Announced |
| May 1, 2019 | $6M Series A | Alexander Hoffmann | Alpana Ventures, Fyrefly VC, Tomahawk.vc | Announced |
| Dec 1, 2016 | $1M Seed | — | Alpana Ventures, Fyrefly VC, Maximon, Tomahawk.vc, Chris Wang | Announced |
Altoida is a health technology company developing the Digital NeuroMarker Platform, an AI-powered, augmented reality (AR)-based diagnostic tool for early detection of neurological conditions like Mild Cognitive Impairment (MCI) and Alzheimer's disease.[1][2][6] The platform delivers a 10-minute, self-administered assessment via smartphone or tablet, capturing hundreds of digital biomarkers from motor, speech, AR, and cognitive domains to provide objective, real-time insights superior to traditional pen-and-paper tests.[1][3][6] It serves clinicians, pharmaceutical researchers, and patients by enabling faster clinical trial enrichment, treatment monitoring, and disease progression tracking, with applications already in global studies and clinics across the US, Japan, Europe, and Brazil.[1][4][5] Backed by over 20 years of research involving nearly 20,000 participants, Altoida has raised $20.3M in an upsized Series A, earned FDA Breakthrough Device Designation and Class II clearance, and achieved up to 94% accuracy in predicting Alzheimer's up to 10 years prior.[2][3][5]
Altoida emerged from more than two decades of scientific research in neuroscience, digital biomarkers, and AI, culminating in a proprietary platform validated through tens of thousands of assessments and over 200 independent studies.[1][4][5] Founded as a privately held, venture-backed diagnostics company based in Washington, DC, it was led by CEO Travis Bond and an international team of neuroscientists, computer scientists, and medical professionals.[2][5] The idea stemmed from limitations in traditional neuropsychology tests—lacking sensitivity for early MCI detection and requiring hours with specialists—pioneering AR to simulate real-world activities of daily living for precise, sensor-based measurements.[6][7] Early traction included peer-reviewed publications in journals like Nature Digital Medicine, FDA clearances, CE Mark approval, and adoption by global pharma leaders for clinical trials, with investments from firms like Hikma Ventures, M-Ventures, and GreySky Venture Partners marking pivotal growth.[1][2][5]
Altoida rides the convergence of AI, AR, and digital health in precision neurology, addressing a market where Alzheimer's and related dementias affect 47 million people globally, projected to double in 20 years amid rising demand for early diagnostics.[2][6] Its timing aligns with smartphone ubiquity enabling remote, scalable assessments, bypassing specialist shortages and long wait times in traditional care.[6] Favorable forces include FDA support for digital biomarkers, pharma's push for efficient trials amid high ADRD failure rates, and growing acceptance of AI in medicine, as seen in publications like Nature Digital Medicine.[1][7] Altoida influences the ecosystem by defining a new category in cognitive diagnostics, empowering clinicians with real-time tools, accelerating drug development, and paving the way for broader CNS applications, potentially reshaping neurodegenerative care standards.[1][4][7]
Altoida's validated platform positions it to dominate early cognitive detection, with expansion into additional diseases, deeper pharma integrations, and global clinic scaling on the horizon.[1][6] Trends like AI advancements, wearable sensor proliferation, and value-based care will amplify its edge, especially as Alzheimer's therapies advance and demand objective monitoring grows.[2][7] Its influence may evolve from research tool to standard-of-care diagnostic, compounding value through data flywheels and partnerships, solidifying its role in revolutionizing brain health from detection to intervention.[1][4] This builds on its foundation as a pioneer turning decades of science into accessible, transformative neurology tech.